Noven To Present at UBS Global Life Sciences Conferencee

-- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) ) today announced that Robert Strauss, Noven’s President, CEO & Chairman, is scheduled to provide an update on Noven’s business and prospects at the UBS Global Life Sciences Conference in New York City on Tuesday, September 25th at 8:00 a.m. ET. The public is invited to listen to the presentation live via webcast at, and a replay will be available for at least two weeks at the same site.

About Noven
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, has established itself as a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Its commercialized transdermal products include Vivelle-Dot® (estradiol transdermal system), the most prescribed estrogen patch in the U.S., and Daytrana™ (methylphenidate transdermal system), the first and only patch approved for the treatment of ADHD.

With the acquisition of JDS Pharmaceuticals in August 2007, Noven has become a broader-based specialty pharmaceutical company with the infrastructure, products and category expertise to market and sell products itself, and with a substantially enhanced late-stage product pipeline.

See for additional information.

Alina Bowman
Investor Relations Coordinator